X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES DR. DATSONS LABS VENUS REMEDIES/
DR. DATSONS LABS
 
P/E (TTM) x -677.5 -10.9 - View Chart
P/BV x 0.2 0.2 122.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   DR. DATSONS LABS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
DR. DATSONS LABS
Mar-14
VENUS REMEDIES/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs218126 173.6%   
Low Rs8231 265.7%   
Sales per share (Unadj.) Rs365.6133.0 274.9%  
Earnings per share (Unadj.) Rs1.50.2 980.2%  
Cash flow per share (Unadj.) Rs37.96.6 573.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.5128.8 297.0%  
Shares outstanding (eoy) m11.4431.66 36.1%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x0.40.6 69.7%   
Avg P/E ratio x101.0516.1 19.6%  
P/CF ratio (eoy) x4.011.8 33.4%  
Price / Book Value ratio x0.40.6 64.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,7172,477 69.3%   
No. of employees `0001.0NA-   
Total wages/salary Rs m32456 579.3%   
Avg. sales/employee Rs Th4,100.7NM-  
Avg. wages/employee Rs Th318.0NM-  
Avg. net profit/employee Rs Th16.7NM-  
INCOME DATA
Net Sales Rs m4,1834,211 99.3%  
Other income Rs m2079 25.5%   
Total revenues Rs m4,2034,289 98.0%   
Gross profit Rs m812569 142.7%  
Depreciation Rs m417204 203.9%   
Interest Rs m380430 88.3%   
Profit before tax Rs m3513 276.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m186 296.7%   
Profit after tax Rs m175 354.2%  
Gross profit margin %19.413.5 143.7%  
Effective tax rate %51.648.0 107.4%   
Net profit margin %0.40.1 356.5%  
BALANCE SHEET DATA
Current assets Rs m2,7716,852 40.4%   
Current liabilities Rs m1,9316,711 28.8%   
Net working cap to sales %20.13.3 599.2%  
Current ratio x1.41.0 140.5%  
Inventory Days Days125161 77.7%  
Debtors Days Days54318 16.9%  
Net fixed assets Rs m5,3283,673 145.1%   
Share capital Rs m114317 36.1%   
"Free" reserves Rs m4,1773,761 111.1%   
Net worth Rs m4,3764,078 107.3%   
Long term debt Rs m1,9111,671 114.3%   
Total assets Rs m8,42812,633 66.7%  
Interest coverage x1.11.0 106.1%   
Debt to equity ratio x0.40.4 106.5%  
Sales to assets ratio x0.50.3 148.9%   
Return on assets %4.73.4 136.7%  
Return on equity %0.40.1 330.0%  
Return on capital %6.67.7 86.0%  
Exports to sales %022.9 0.0%   
Imports to sales %20.514.3 143.6%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs m858602 142.6%   
Fx inflow Rs m0964 0.0%   
Fx outflow Rs m858607 141.4%   
Net fx Rs m-858357 -240.5%   
CASH FLOW
From Operations Rs m4691,345 34.9%  
From Investments Rs m29-2,256 -1.3%  
From Financial Activity Rs m-464-1,200 38.6%  
Net Cashflow Rs m35-2,111 -1.6%  

Share Holding

Indian Promoters % 32.9 4.5 725.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.0 -  
FIIs % 0.6 1.4 43.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 94.1 70.6%  
Shareholders   20,121 20,807 96.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 19, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS